MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
$196,515K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturity and sales of available-...
Increase in other assets
Increase in inventory
Others
Negative Cash Flow Breakdown
Purchase of investments
Decrease in deferred revenue
Decrease in accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Loss on investment in arrowhead pharmaceuticals
-
-
0
-17,293
Non-cash write-off of prepaid deposits
-
-
0
17,041
Net income (loss)
-4,890
330,959
-282,847
-430,563
(gain) loss on debt extinguishment
-
-
155,475
-138,613
Non-cash inventory write-downs for excess and obsolescence
-
-
165,257
-
Stock-based compensation
24,472
29,399
30,016
93,380
In-kind milestone payment to arrowhead pharmaceuticals
-
-
0
50,000
Depreciation and amortization
10,409
10,594
5,253
39,268
Non-cash interest expense
9,394
9,612
13,532
-
Non-cash inventory write-downs for obsolescence
11,599
-
-
-
Reduction in the carrying amounts of the right of use assets
3,212
3,110
2,625
11,326
Non-cash termination charges
-
-
0
0
Change in the fair value of derivatives
-
-
11,100
-11,100
Impairment of strategic investments
-
-
0
-
Loss on strategic investments
-448
-1,712
-
-
Gain from sale of priority review voucher
-
-
0
-
Accretion of investment discount, net
-905
-530
-380
-4,911
Other
10
1,288
-2,616
-4,439
Decrease (increase) in accounts receivable
-17,993
-3,416
2,494
-206,249
Decrease in manufacturing-related deposits and prepaids
-25,792
-43,487
-11,768
-67,072
Increase in inventory
-39,911
69,756
-18,475
319,568
Increase in other assets
-82,387
14,547
-20,286
100,070
Decrease in deferred revenue
-32,127
-274,916
41,858
30,193
Decrease in accounts payable
-19,394
-210,465
-
-
(decrease) increase in accrued expenses
22,695
-60,026
-
-
Increase (decrease) in accounts payable, accrued expenses, lease liabilities and other liabilities
-
-
249,616
-145,347
(decrease) increase in lease liabilities and other liabilities
6,084
-3,444
-
-
Net cash used in operating activities
197,070
-202,683
131,206
-336,685
Purchase of available-for-sale securities
-
170,197
0
44,658
Purchase of investments
351,045
-
-
-
Proceeds from sale of investment in arrowhead pharmaceuticals
-
-
0
174,095
Maturity and sales of available-for-sale securities
88,031
38,888
99,936
195,935
Purchase of property and equipment
555
2,081
3,591
98,381
Purchase of intangible assets
0
1,000
138
7,738
Proceeds from sale of priority review voucher
-
-
0
-
Acquisition of strategic investments
0
0
0
-245,819
Net cash provided by investing activities
-93,372
-134,390
96,207
-26,566
Common stock issuance costs
-
-
110
2,276
Repayment of 2027 notes, including debt extinguishment costs
-
-
35,085
123,333
Repurchases of common stock, net of excise tax
-
-
0
25,013
Proceeds from issuance of common stock
-
-
0
20,000
Debt issuance costs for the august 2025 exchange and december 2025 exchange (defined in note 13)
-
-
4,273
12,787
Proceeds from exercise of stock options and purchase of stock under the employee stock purchase program
0
241
308
18,395
Proceeds from borrowings under the revolving credit facility
175,000
250,000
-
-
Settlement of capped call share options for 2024 notes
-
-
0
-
Repayments of borrowings under the revolving credit facility
175,000
250,000
-
-
Payment on maturity of 2024 notes
-
-
0
-
Repurchases of common stock
0
-
-
-
Debt conversion costs for 2024 notes
-
-
0
-
Payments related to obtaining revolving credit facility
0
0
48
4,122
Net cash provided by financing activities
0
241
-39,208
-129,136
Decrease in cash, cash equivalents and restricted cash
103,698
-336,832
188,205
-492,387
Beginning of period
477,575
526,177
-
-
End of period
581,273
-
-
-
Cash and cash equivalents
571,148
-
-
-
Beginning of year
-
-
1,118,589
-
Restricted cash in other assets
10,125
-
-
-
End of year
-
-
814,407
-
Total cash, cash equivalents and restricted cash
581,273
477,575
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Increase in other assets
-$82,387K
Increase in inventory
-$39,911K
Decrease in
manufacturing-related deposits and...
-$25,792K
Stock-based compensation
$24,472K
(decrease) increase in
accrued expenses
$22,695K
Decrease (increase) in
accounts receivable
-$17,993K
Non-cash inventory
write-downs for...
$11,599K
Depreciation and
amortization
$10,409K
Non-cash interest
expense
$9,394K
(decrease) increase in
lease liabilities and...
$6,084K
Reduction in the carrying
amounts of the right of...
$3,212K
Loss on strategic
investments
-$448K
Net cash used in
operating activities
$197,070K
Canceled cashflow
$57,326K
Decrease in cash, cash
equivalents and restricted...
$103,698K
Canceled cashflow
$93,372K
Decrease in deferred
revenue
-$32,127K
Decrease in accounts
payable
-$19,394K
Net income (loss)
-$4,890K
Accretion of investment
discount, net
-$905K
Other
$10K
something is missing
$170,197K
Maturity and sales of
available-for-sale securities
$88,031K
Net cash provided by
investing activities
-$93,372K
Canceled cashflow
$258,228K
Purchase of investments
$351,045K
Purchase of property and
equipment
$555K
Buy us a coffee
logo (1) copy-svg
Sarepta Therapeutics, Inc. (SRPT)
logo (1) copy-svg
Sarepta Therapeutics, Inc. (SRPT)